Marinomed Biotech Aktie 44956022 / ATMARINOMED6
| Kurse + Charts + Realtime | News + Analysen | Fundamental | Unternehmen | zugeh. Wertpapiere | Aktion | |
|---|---|---|---|---|---|---|
| Kurs + Chart | Chart (gross) | News + Adhoc | Bilanz/GuV | Termine | Strukturierte Produkte | Portfolio |
| Times + Sales | Chartvergleich | Analysen | Schätzungen | Profil | Trading-Depot | Watchlist |
| Börsenplätze | Realtime Push | Kursziele | Dividende/GV | |||
| Historisch | Analysen | |||||
|
06.10.2025 14:56:43
|
EQS-Adhoc: Marinomed Biotech AG begins reviewing strategic options for the Marinosolv platform
|
EQS-Ad-hoc: Marinomed Biotech AG / Key word(s): Strategic Company Decision Ad hoc announcement Marinomed Biotech AG begins reviewing strategic options for the Marinosolv platform
Korneuburg, October 6, 2025 - Ad hoc announcement Following the successful recent capital measures, the Management Board of Marinomed Biotech AG, with the approval of the Supervisory Board, today decided to begin reviewing strategic options for the Marinosolv platform. Depending on the progress of the review, the evaluation process could include strategic partnerships for the two projects Budesolv and Tacrosolv, as well as the involvement of a strategist. Marinomed is working with an experienced consulting firm to support this process.
+++ End of ad-hoc announcement +++
About Marinomed Biotech AG Marinomed Biotech AG is an Austrian, science-based biotech company with a growing development pipeline. The Company develops innovative patent-protected products based on the Marinosolv® platform. The Marinosolv® technology improves the solubility and bioavailability of hardly soluble compounds and is used to develop new therapeutics for autoreactive immune disorders. The Company is headquartered in Korneuburg, Austria, and is listed on the Vienna Stock Exchange (VSE:MARI). For further information, please visit: https://www.marinomed.com.
For further inquiries contact:
Disclaimer This press release contains forward-looking statements, which are based on current views, expectations and projections of the management of Marinomed Biotech AG about future events. These forward-looking statements are subject to risks, uncertainties and assumptions that could cause actual results, performance or events to differ materially from those described in, or expressed or implied by, such statements. The current views, expectations and projections of the management of Marinomed Biotech AG may be identified by the context of such statements or words such as “anticipate,” “believe”, “estimate”, “expect”, “intend”, “plan”, “project” and “target”. Forward-looking statements are only valid as of the date they are made and Marinomed Biotech AG does not assume any obligation to update, review or revise any forward-looking statements contained in this press release whether as a result of new information, future developments or otherwise. Marinomed and Marinosolv® are registered trademarks of Marinomed Biotech AG. These trademarks may be owned or licensed in select locations only. End of Inside Information Information and Explanation of the Issuer to this announcement: Ad hoc announcement Marinomed Biotech AG begins reviewing strategic options for the Marinosolv platform
Korneuburg, October 6, 2025 - Ad hoc announcement Following the successful recent capital measures, the Management Board of Marinomed Biotech AG, with the approval of the Supervisory Board, today decided to begin reviewing strategic options for the Marinosolv platform. Depending on the progress of the review, the evaluation process could include strategic partnerships for the two projects Budesolv and Tacrosolv, as well as the involvement of a strategist. Marinomed is working with an experienced consulting firm to support this process.
+++ End of ad-hoc announcement +++
About Marinomed Biotech AG Marinomed Biotech AG is an Austrian, science-based biotech company with a growing development pipeline. The Company develops innovative patent-protected products based on the Marinosolv® platform. The Marinosolv® technology improves the solubility and bioavailability of hardly soluble compounds and is used to develop new therapeutics for autoreactive immune disorders. The Company is headquartered in Korneuburg, Austria, and is listed on the Vienna Stock Exchange (VSE:MARI). For further information, please visit: https://www.marinomed.com.
For further inquiries contact:
Disclaimer This press release contains forward-looking statements, which are based on current views, expectations and projections of the management of Marinomed Biotech AG about future events. These forward-looking statements are subject to risks, uncertainties and assumptions that could cause actual results, performance or events to differ materially from those described in, or expressed or implied by, such statements. The current views, expectations and projections of the management of Marinomed Biotech AG may be identified by the context of such statements or words such as “anticipate,” “believe”, “estimate”, “expect”, “intend”, “plan”, “project” and “target”. Forward-looking statements are only valid as of the date they are made and Marinomed Biotech AG does not assume any obligation to update, review or revise any forward-looking statements contained in this press release whether as a result of new information, future developments or otherwise. Marinomed and Marinosolv® are registered trademarks of Marinomed Biotech AG. These trademarks may be owned or licensed in select locations only.
06-Oct-2025 CET/CEST News transmitted by EQS Group. www.eqs.com |
| Language: | English |
| Company: | Marinomed Biotech AG |
| Hovengasse 25 | |
| 2100 Korneuburg | |
| Austria | |
| Phone: | +43 2262 90300 |
| E-mail: | office@marinomed.com |
| Internet: | www.marinomed.com |
| ISIN: | ATMARINOMED6 |
| WKN: | A2N9MM |
| Listed: | Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt, Munich, Stuttgart, Tradegate Exchange; Vienna Stock Exchange (Official Market) |
| EQS News ID: | 2208704 |
| End of Announcement | EQS News Service |
|
|
2208704 06-Oct-2025 CET/CEST
Nachrichten zu Marinomed Biotech AG
|
14.11.25 |
Börse Wien: ATX Prime beendet den Handel im Minus (finanzen.ch) | |
|
14.11.25 |
Wiener Börse-Handel ATX Prime verliert am Nachmittag (finanzen.ch) | |
|
14.11.25 |
Schwache Performance in Wien: ATX Prime präsentiert sich mittags leichter (finanzen.ch) | |
|
14.11.25 |
Freitagshandel in Wien: ATX Prime fällt zum Start des Freitagshandels zurück (finanzen.ch) | |
|
13.11.25 |
Börse Wien: ATX Prime beendet die Donnerstagssitzung in der Verlustzone (finanzen.ch) | |
|
13.11.25 |
Donnerstagshandel in Wien: ATX Prime liegt nachmittags im Minus (finanzen.ch) | |
|
13.11.25 |
Optimismus in Wien: ATX Prime am Mittag in der Gewinnzone (finanzen.ch) | |
|
13.11.25 |
Wiener Börse-Handel: ATX Prime zeigt sich zum Start fester (finanzen.ch) |
Analysen zu Marinomed Biotech AG
ETF-Sparpläne boomen – aber wie fängst du richtig an und welche Produkte passen wirklich zu dir? Im ETF-Panel vom Börsentag 2025 in Zürich diskutieren Experten über alles, was du zu ETFs in der Schweiz wissen musst: von den Grundlagen bis zu aktiven ETFs, Themen-ETFs und den versteckten Kosten bei Brokern.
Du erfährst:
🔸Was ein ETF ist, warum er so transparent und günstig ist und wie du mit Sparplänen schon mit kleinen Beträgen (z.B. 50 CHF) Vermögen aufbauen kannst.
🔸Wie du dein ETF-Portfolio aufbaust: MSCI World vs. All Country, Emerging Markets, Themen-ETFs wie AI, Klima oder Gesundheit – und wann „Pfeffer im Depot“ Sinn macht.
🔸Warum „Time in the market“ wichtiger ist als Market Timing und wieso Finanzbildung und einfache Erklärungen für Einsteiger so entscheidend sind.
🔸Wie du Kosten wirklich vergleichst: TER, Courtage, FX-Gebühren, Stempelsteuer & Co. – und worauf du bei Schweizer Brokern und ETF-Anbietern achten solltest.
🔸Ob aktive ETFs eine echte Chance auf Mehrertrag bieten oder nur ein teurer Trend sind – inklusive ehrlicher Einschätzungen der Anbieter.
🔸Wenn du in der Schweiz lebst, ETF-Sparpläne nutzen willst und Schritt für Schritt Vermögen für Rente, Eigenheim oder dein Traumauto aufbauen möchtest, ist dieses Panel dein perfekter Einstieg
👉🏽 Jetzt auch auf BXplus anmelden und von exklusiven Inhalten rund um Investment & Trading profitieren!
Inside Trading & Investment
Mini-Futures auf SMI
Aktien in diesem Artikel
| Marinomed Biotech AG | 19.85 | 1.02% |
|
Meistgelesene Nachrichten
Top-Rankings
Börse aktuell - Live Ticker
SMI und DAX gehen tiefrot ins Wochennde -- Wall Street schliesst uneins -- Asiens Börsen letztlich im MinusDer heimische sowie der deutsche Aktienmarkt notierten zum Wochenschluss deutlich tiefer. Die Wall Street zeigte sich zum Wochenende mit unterschiedlicher Tendenz. An Asiens Börsen ging es am Freitag teils deutlich nach unten.